Table 1.

Patient characteristics.

Patient	Sex	Age (y)	Primary tumor location	Clinical stage (TNM)a	Total doses of IMRT (Gy)	Total number of fractions
Intraoral stent (−)
1	M	59	MS	T4bN2cM0	66	33
2	F	81	MS	T4aN0M1b	66	33
3	M	66	ES	T4aN0M0	66	33
4	F	86	MS	T4aN0M0	66	33
5	M	58	OP	T2N2cM0	66	33
6	M	81	OP	T3N2cM0	66	33
7	M	69	Lx	T3N2cM0c	60	30
8	M	81	Lx	T4aN1M0c	60	30
9	F	77	NC	T1N0M0	70	35
10	F	71	OC	T4bN0M0	70	33
11	F	77	MS	T3N0M0	66	33
12	M	81	MS	T4aN1M0	66	33
Intraoral stent (+)
13	M	48	MS	T4bN0M0	66	33
14	M	67	MS	T3N0M0	66	33
15	M	75	ES	T3N0M0	66	33
16	F	61	NC	T3N0M0c	40	20
17	M	72	ES	T2N0M0	66	33
18	M	31	MS	T2N0M0	66	33

^aStaging was performed based on the systematic TNM classification of the American Joint Committee on Cancer (seventh edition).

^bA lung nodule was later confirmed to be a metastasis after radiotherapy.

^cRadiotherapy was performed as an adjuvant therapy after surgery; the pathological stages are shown in the table.

Abbreviations: IMRT, intensity-modulated radiation therapy; MS, maxillary sinus; ES, ethmoid sinus; OP, oropharynx; Lx, Larynx; NC, nasal cavity; OC, oral cavity.